About: COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study
Creator	Arnold, Roland Lee, Alvin Lee, Lee, Y Lee, Ming Lee, Rebecca Bisht, Vartika Booth, Stephen Briggs, Adam Briggs, Sarah Campton, Naomi Cazier, J-B Cazier, Jean-Baptiste Cheng, Vinton Collins, Graham Curley, Helen Curley, H Dphil, L Y W Earwaker, Philip Fittall, Matthew Gennatas, Spyridon Goel, Anshita Goel, A Hartley, Simon Hughes, Daniel Kerr, David Kerr, Rachel Lennard, Y Mckenzie, Hayley Middleton, C Middleton, Chris Middleton, Gary Msci, Starkey Murugaesu, Nirupa Newsom-Davis, Tom Olsson-Brown, Anna Palles, Claire Palles, C Phd, Arnold Powles, Thomas Purshouse, Karin Protheroe, Emily Sharma-Oates, Archana Sivakumar, Shivan Smith, Ashley Sivakumar, S Starkey, Thomas Topping, Oliver Turnbull, Chris Várnai, Csilla
Source	Elsevier; Medline; PMC
abstract	BACKGROUND: Patients with cancer are purported to have poor COVID-19 outcomes. However, cancer is a heterogeneous group of diseases, encompassing a spectrum of tumour subtypes. The aim of this study was to investigate COVID-19 risk according to tumour subtype and patient demographics in patients with cancer in the UK. METHODS: We compared adult patients with cancer enrolled in the UK Coronavirus Cancer Monitoring Project (UKCCMP) cohort between March 18 and May 8, 2020, with a parallel non-COVID-19 UK cancer control population from the UK Office for National Statistics (2017 data). The primary outcome of the study was the effect of primary tumour subtype, age, and sex and on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) prevalence and the case–fatality rate during hospital admission. We analysed the effect of tumour subtype and patient demographics (age and sex) on prevalence and mortality from COVID-19 using univariable and multivariable models. FINDINGS: 319 (30·6%) of 1044 patients in the UKCCMP cohort died, 295 (92·5%) of whom had a cause of death recorded as due to COVID-19. The all-cause case–fatality rate in patients with cancer after SARS-CoV-2 infection was significantly associated with increasing age, rising from 0·10 in patients aged 40–49 years to 0·48 in those aged 80 years and older. Patients with haematological malignancies (leukaemia, lymphoma, and myeloma) had a more severe COVID-19 trajectory compared with patients with solid organ tumours (odds ratio [OR] 1·57, 95% CI 1·15–2·15; p<0·0043). Compared with the rest of the UKCCMP cohort, patients with leukaemia showed a significantly increased case–fatality rate (2·25, 1·13–4·57; p=0·023). After correction for age and sex, patients with haematological malignancies who had recent chemotherapy had an increased risk of death during COVID-19-associated hospital admission (OR 2·09, 95% CI 1·09–4·08; p=0·028). INTERPRETATION: Patients with cancer with different tumour types have differing susceptibility to SARS-CoV-2 infection and COVID-19 phenotypes. We generated individualised risk tables for patients with cancer, considering age, sex, and tumour subtype. Our results could be useful to assist physicians in informed risk–benefit discussions to explain COVID-19 risk and enable an evidenced-based approach to national social isolation policies. FUNDING: University of Birmingham and University of Oxford.
has issue date	2020-08-24(xsd:dateTime)
bibo:doi	10.1016/s1470-2045(20)30442-3
bibo:pmid	32853557
has license	no-cc
sha1sum (hex)	a365f50c48ece25c57893f74e504b7fdada94efa
schema:url	https://doi.org/10.1016/s1470-2045%2820%2930442-3
resource representing a document's title	COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study
has PubMed Central identifier	PMC7444972
has PubMed identifier	32853557
schema:publication	Lancet Oncol
resource representing a document's body	covid:a365f50c48ece25c57893f74e504b7fdada94efa#body_text
is schema:about of	named entity 'demographics' named entity 'risk' named entity 'demographics' named entity 'primary' named entity 'AIM' named entity 'STUDY' named entity 'SUBTYPE' named entity 'OUTCOMES' named entity 'PATIENTS' named entity 'tumour' named entity 'diseases' named entity 'cancer' named entity 'tumour' named entity 'cancer' named entity 'COVID-19' named entity 'cancer' named entity 'morbidity' named entity 'soft tissue' named entity 'COVID-19 pandemic' named entity 'infection' named entity 'multi-organ failure' named entity 'National Research Ethics Service' named entity 'throat swab' named entity 'haematological malignancies' named entity 'older age' named entity 'haematological cancers' named entity 'metastatic cancer' named entity 'haematological cancers' named entity 'oral cavity' named entity 'tumour' named entity 'lung cancer' named entity 'tumour'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software